Endometriosis

Summary

GlobalData, the industry analysis specialist's new report, Endometriosis - Drug Pipeline Analysis and Market Forecasts to 2016 is an essential source of information and analysis on the global endometriosis market, a key segment within the pharmaceutical and healthcare industry. This pharma report identifies the key trends shaping and driving the global endometriosis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global endometriosis sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.

Scope

The scope of the report includes:

• Annualized global endometriosis market revenues data from 2001 to 2009, forecast forward for 7 years to 2016.
• Geographic markets covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France, and Japan.
• Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.
• Analysis of the current and future market competition in the global endometriosis market. Key companies covered include Bayer AG, Pfizer, Aeterna Zentaris, Neurocrine Biosciences Inc., KV Pharmaceutical company.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future market associated with endometriosis.

Reasons to buy:

• The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
• Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global endometriosis market.
• Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global endometriosis market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What's the next big thing in the global endometriosis market landscape? - Identify, understand and capitalize.

Contents

• 1 Table of contents
  • 1.1 List of Tables
  • 1.2 List of Figures
• 2 Endometriosis: Market Characterization
  • 2.1 Overview
  • 2.2 Endometriosis Market Size
  • 2.3 Endometriosis Market Forecast and CAGR
  • 2.4 Drivers and Barriers for Endometriosis Market
    • 2.4.1 Drivers for Endometriosis Market
    • 2.4.2 Barriers for Endometriosis Market
  • 2.5 Opportunity and Unmet Need
  • 2.6 Key Takeaway
• 3 Endometriosis Market: Competitive Assessment
  • 3.1 Overview
  • 3.2 Strategic Competitor Assessment
  • 3.3 Major Therapies in the Endometriosis Market
    • 3.3.1 Non-steroidal anti-inflammatory drugs (NSAIDs) for Endometriosis
    • 3.3.2 Gonadotropin-releasing hormone (GnRH) agonists for Endometriosis
    • 3.3.3 Birth Control Hormones for Endometriosis
    • 3.3.4 Progestins for Endometriosis
  • 3.4 Key Takeaway
• 4 Endometriosis Market: Pipeline Assessment
  • 4.1 Overview
  • 4.2 Strategic Pipeline Assessment
    • 4.2.1 Technology Trends Analytic Framework
  • 4.3 Endometriosis Therapeutics - Promising Drugs Under Clinical Development
  • 4.4 Molecule Profile for Promising Drugs under Clinical Development
    • 4.4.1 Visanne
    • 4.4.2 Proellex
    • 4.4.3 Elagolix (NBI-56418)
    • 4.4.4 MPI-676
  • 4.5 Endometriosis Therapeutics Market - Clinical Pipeline by Therapeutic Class
  • 4.6 Endometriosis Disease Pipeline - Pipeline by Clinical Phases of Development
    • 4.6.1 Endometriosis Therapeutics - Phase III and Regulatory Filed Clinical Pipeline
    • 4.6.2 Endometriosis Therapeutics - Phase II Clinical Pipeline
    • 4.6.3 Endometriosis Therapeutics - Phase I Clinical Pipeline
    • 4.6.4 Endometriosis Therapeutics - Preclinical Pipeline
    • 4.6.5 Endometriosis Therapeutics - Drug Discovery Pipeline
  • 4.7 Key Takeaway
• 5 Global Endometriosis Market: Implications for Future Market Competition
• 6 Global Endometriosis Market: Future Players in Endometriosis Market
  • 6.1 Introduction
  • 6.2 Bayer AG
    • 6.2.1 Company Overview
    • 6.2.2 Business Description
  • 6.3 Pfizer Inc
    • 6.3.1 Company Overview
    • 6.3.2 Business Description
  • 6.4 AEterna Zentaris Inc
    • 6.4.1 Company Overview
    • 6.4.2 Business Description
  • 6.5 Neurocrine Biosciences, Inc
    • 6.5.1 Company Overview
    • 6.5.2 Business Description
  • 6.6 KV Pharmaceutical Company
    • 6.6.1 Company Overview
    • 6.6.2 Business Description
• 7 Global Endometriosis Market: Appendix
  • 7.1 Definitions
  • 7.2 Acronyms
  • 7.3 Research Methodology
    • 7.3.1 Coverage
    • 7.3.2 Secondary Research
    • 7.3.3 Forecasting
    • 7.3.4 Primary Research
    • 7.3.5 Expert Panels
  • 7.4 Contact Us
  • 7.5 Disclaimer
  • 7.6 Sources
• List of Tables
  • Table 1: Global Endometriosis Market, Historic Revenue ($m), 2001-2009
  • Table 2: Global Endometriosis Market, Revenue Forecasts ($ m), 2009-2016
  • Table 3: Endometriosis Therapeutics - Most Promising Drugs Under Clinical Development, 2010
  • Table 4: Endometriosis Therapeutics - Phase III Clinical Pipeline, 2010
  • Table 5: Endometriosis Therapeutics - Phase II Clinical Pipeline, 2010
  • Table 6: Endometriosis Therapeutics - Phase I Clinical Pipeline, 2010
  • Table 7: Endometriosis Therapeutics - Preclinical Pipeline, 2010
  • Table 8: Endometriosis Therapeutics - Drug Discovery Pipeline, 2010
  • Table 9: Bayer AG - Women's Healthcare Pipeline Products, 2010
  • Table 10: Bayer AG - Endometriosis Pipeline Products, 2010
  • Table 11: Pfizer Inc - Women's Health Pipeline Products, 2010
  • Table 12: Pfizer Inc - Endometriosis Pipeline Products, 2010
  • Table 13: AEterna Zentaris Inc. - Women's Health Pipeline Products, 2010
  • Table 14: AEterna Zentaris Inc. - Endometriosis Pipeline Products, 2010
  • Table 15: Neurocrine Biosciences, Inc. - Women's Health Pipeline Products, 2010
  • Table 16: Neurocrine Biosciences, Inc. - Endometriosis Pipeline Products, 2010
  • Table 17: KV Pharmaceutical Company - Women's Health Pipeline Products, 2010
  • Table 18: KV Pharmaceutical Company - Endometriosis Pipeline Products, 2010
• List of Figures
  • Figure 1: Global Endometriosis Market Forecasts ($m), 2001-2016
  • Figure 2: Endometriosis Market - Opportunity and Unmet Need, 2010
  • Figure 3: Endometriosis Market - Strategic Competitor Assessment, 2010
  • Figure 4: Technology Trends Analytic Framework of the Endometriosis Pipeline, 2010
  • Figure 5: Technology Trends Analytic Framework of the Endometriosis Pipeline - Description, 2010
  • Figure 6: Endometriosis Market - Clinical Pipeline by Mechanism Of Action, 2010
  • Figure 7: Endometriosis Pipeline by Phase of Clinical Development, 2010
  • Figure 8: Endometriosis Therapeutics Market - Strategic Competitor Assessment, 2010
  • Figure 9: Endometriosis Therapeutics Market - Clinical Pipeline by Company, 2010
  • Figure 10: GlobalData Methodology
  • Figure 11: GlobalData Market Forecasting Model